IGM Biosciences to Present at Three Upcoming Investor Conferences
November 09, 2020 07:00 ET
|
IGM Biosciences
MOUNTAIN VIEW, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences Announces Third Quarter 2020 Financial Results and Provides Corporate Update
November 05, 2020 07:02 ET
|
IGM Biosciences
MOUNTAIN VIEW, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- - Initial Data from Phase 1 Trial of IGM-2323 in Relapsed/refractory Non-Hodgkin’s Lymphoma to be Presented at the 62nd American Society of...
IGM Biosciences to Present First Clinical Data from IGM-2323 in Non-Hodgkin’s Lymphoma at 2020 ASH Annual Meeting
November 04, 2020 09:20 ET
|
IGM Biosciences
MOUNTAIN VIEW, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences Initiates First-in-Human Clinical Trial of IGM-8444 for the Treatment of Solid Cancers and Non-Hodgkin’s Lymphoma
September 30, 2020 07:00 ET
|
IGM Biosciences
MOUNTAIN VIEW, Calif., Sept. 30, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
AbCellera and IGM Biosciences Announce Multi-Year Antibody Discovery Collaboration
September 24, 2020 16:01 ET
|
IGM Biosciences
VANCOUVER, British Columbia and MOUNTAIN VIEW, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) -- AbCellera and IGM Biosciences, Inc. (Nasdaq: IGMS), announced today that they have entered into a multi-year,...
IGM Biosciences to Present at Four Upcoming Investor Conferences
September 02, 2020 07:00 ET
|
IGM Biosciences
MOUNTAIN VIEW, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences Announces Second Quarter 2020 Financial Results and Provides Corporate Update
August 06, 2020 16:08 ET
|
IGM Biosciences
- IND for IGM-8444 for treatment of patients with solid cancers cleared by FDA - - Kathy Miller, Ph.D., appointed Vice President, Antibody Discovery - - Phase I clinical trial of IGM-2323...
IGM Biosciences to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
August 04, 2020 07:00 ET
|
IGM Biosciences
MOUNTAIN VIEW, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences to Present at the Jefferies 2020 Healthcare Conference
May 28, 2020 07:00 ET
|
IGM Biosciences
MOUNTAIN VIEW, Calif., May 28, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences to Present at the 2020 RBC Capital Markets Global Healthcare Conference
May 12, 2020 07:00 ET
|
IGM Biosciences
MOUNTAIN VIEW, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...